NDA 210563 · Pharmacyclics LLC
Imbruvica
Ibrutinib · Oral · Kinase Inhibitor
Accelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Feb 16, 2018
Approved uses
10
Original approval plus efficacy supplements
Registered trials
381
49 Phase 3, 31 recruiting
FAERS reports
80,997
63,021 serious, 13,832 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 21, 2025.
IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ). 1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 1. 2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion. 1. 3 Waldenström’s Macroglobulinemia IMBRUVICA is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 1. 4 Chronic Graft versus Host Disease IMBRUVICA is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
Mechanism: Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 18, 2023 Supplement 17 · Efficacy OrphanLetterLabel
- Aug 24, 2022 Supplement 14 · Efficacy · priority review OrphanLabel
- Aug 24, 2022 Supplement 12 · Efficacy · priority review OrphanLabel
- Aug 24, 2022 Supplement 13 · Efficacy · priority review Orphan
- Dec 18, 2020 Supplement 9 · Efficacy OrphanLetterLabel
- Apr 21, 2020 Supplement 6 · Efficacy · priority review OrphanLabelLetter
- Jan 25, 2019 Supplement 2 · Efficacy · priority review OrphanLabelLetter
- Aug 24, 2018 Supplement 1 · Efficacy · priority review OrphanLabelLetter
- Feb 16, 2018 Original approval · Type 3 - New Dosage Form · priority review Accelerated approvalOrphanLabelLetterReview
- Feb 16, 2018 Original approval · Efficacy · priority review OrphanLabelReview
4 products under this application
- IMBRUVICA · IBRUTINIB 560MG · TABLET, ORAL · Discontinued
- IMBRUVICA · IBRUTINIB 280MG · TABLET, ORAL · Prescription
- IMBRUVICA · IBRUTINIB 420MG · TABLET, ORAL · Prescription
- IMBRUVICA · IBRUTINIB 140MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ibrutinib" as an intervention, any sponsor and status, largest first.
- MACE and BTK InhibitorsNot yet recruiting
University Hospital, CaenAcademic, hospital or other
NCT07923162 · 10,000 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 1, 2027
Drug: ibrutinib; Acalabrutinib and 1 more · For: Hematologic Cancer; MACE; BTK Inhibitors
Sites: Caen, France
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136559 · 1,200 participants (planned) · Start Dec 13, 2023 · Primary completion Sep 7, 2032
Drug: Nemtabrutinib; Ibrutinib and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 206 sites in all
German CLL Study GroupAcademic, hospital or other
NCT02950051 · 926 participants · Start Dec 13, 2016 · Primary completion Feb 29, 2024
Drug: Fludarabine; Cyclophosphamide and 5 more · For: Chronic Lymphocytic Leukemia
Sites: Vienna, Austria; Antwerp, Belgium; Bruges, Belgium · 161 sites in all
- Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Pivotal-lookingActive, not recruiting
German CLL Study GroupAcademic, hospital or other
NCT04608318 · 897 participants (planned) · Start Mar 1, 2021 · Primary completion Sep 2027
Drug: Ibrutinib; Venetoclax and 1 more · For: Chronic Lymphoid Leukemia
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 181 sites in all
- ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaPivotal-lookingStatus unknown
Prof. Dr. M. Dreyling (co-chairman)Academic, hospital or other
NCT02858258 · 870 participants (planned) · Start Jul 2016 · Primary completion May 2021
Drug: R-CHOP/R-DHAP; Ibrutinib (Induction) and 2 more · For: Mantle Cell Lymphoma
Sites: Aalborg, Denmark; Aarhus C, Denmark; Copenhagen, Denmark · 112 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01855750 · 838 participants · Start Sep 3, 2013 · Primary completion Feb 26, 2018
Drug: Ibrutinib; Placebo and 5 more · For: Lymphoma
Sites: Tucson, Arizona; Greenbrae, California; La Jolla, California · 201 sites in all
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT03740529 · 803 participants · Start Mar 15, 2019 · Primary completion Jan 27, 2025
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma and 3 more
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 56 sites in all
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Pivotal-lookingRecruiting
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT05254743 · 737 participants (planned) · Start Jul 22, 2022 · Primary completion Oct 2027
Drug: Pirtobrutinib; Ibrutinib · For: Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell and 1 more
Sites: Anaheim, California; Cerritos, California; Palo Alto, California · 143 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death8,652
- off label use6,069
- fatigue4,780
- diarrhoea4,224
- atrial fibrillation3,926
- pneumonia3,291
- contusion2,827
- incorrect dose administered2,779
- fall2,544
- asthenia2,378
- nausea2,331
- arthralgia2,226
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 5 |
| 2013 | 64 |
| 2014 | 1,286 |
| 2015 | 4,210 |
| 2016 | 4,326 |
| 2017 | 5,376 |
| 2018 | 7,196 |
| 2019 | 8,568 |
| 2020 | 10,342 |
| 2021 | 7,680 |
| 2022 | 13,527 |
| 2023 | 8,225 |
| 2024 | 4,441 |
| 2025 | 3,593 |
| 2026 | 2,158 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Imbruvica (Ibrutinib)
2024 spending
$2.27B
Beneficiaries
15,351
146,416 claims
Per beneficiary
$147,629
$478.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,962,909,304 |
| 2021 | $3,150,225,810 |
| 2022 | $2,853,910,970 |
| 2023 | $2,371,893,292 |
| 2024 | $2,266,252,032 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang M, Salek D, Belada D, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Al-Sawaf O, Stumpf J, Zhang C, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC, Hillmen P, Ghia P, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Comparative Study
- Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Munir T, Girvan S, Cairns DA, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
Melani C, Lakhotia R, Pittaluga S, et al. · N Engl J Med 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Dreyling M, Doorduijn J, Giné E, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.